Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
1,566.00
-45.30 (-2.81%)
Last updated: Nov 16, 2026, 3:29 PM IST
Symbiotec Pharmalab Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Symbiotec Pharmalab stock has a consensus rating of "Strong Buy" and an average price target of ₹1,654. The average 1-year stock price forecast is 5.62% higher than the current stock price, while the lowest is ₹1,540 (-1.66%) and the highest is ₹1,800 (+14.94%).
Price Target: ₹1,654 (+5.62%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Symbiotec Pharmalab stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Financial Forecast
Revenue This Year
11.39B
from 8.69B
Increased by 31.08%
Revenue Next Year
13.51B
from 11.39B
Increased by 18.58%
EPS This Year
22.40
EPS Next Year
29.00
from 22.40
Increased by 29.46%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.